{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:47:03Z","timestamp":1790192823115,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J INFECT DIS"],"published-print":{"date-parts":[[1997,8]]},"DOI":"10.1086\/514177","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T20:23:29Z","timestamp":1198095809000},"page":"S56-S61","source":"Crossref","is-referenced-by-count":36,"title":["Antivirals for Pandemic Influenza"],"prefix":"10.1093","volume":"176","author":[{"given":"Frederick G.","family":"Hayden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"p_2_16","doi-asserted-by":"crossref","unstructured":"Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-Pharmacother 1995; 29:299 0 310. N-acetylneuraminic acid) is consistent with extracellular activity of viral","DOI":"10.1177\/106002809502900312"},{"key":"p_3_17","first-page":"1990","volume":"38","author":"Douglas","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"p_4_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1989.tb06809.x","volume":"37","author":"Peters NL","year":"1989","journal-title":"J Am Geriatr Soc"},{"key":"p_5_19","doi-asserted-by":"crossref","unstructured":"Degelau J, Somani S, Cooper SL, etal Occurrence of adverse effects the sialidase (neuraminidase) and of growth of a wide range of inOuenza and high amantadine concentrations with inOuenza prophylaxis in the A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37:1473 0 nursing home. J Am Geriatr Soc 1990; 38:428 0 32. 9.","DOI":"10.1111\/j.1532-5415.1990.tb03541.x"},{"key":"p_6_20","doi-asserted-by":"crossref","unstructured":"Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophy- 27. Hayden FG, Rollins BS, Madren LK. Anti-inOuenza virus activity of the laxis of inOuenza in a retirement home. J Am Geriatr Soc 1991; 33: neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in 700 0 5. human respiratory epithelium. Antiviral Res 1994; 25:123 0 31.","DOI":"10.1016\/0166-3542(94)90101-5"},{"key":"p_7_21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/AAC.39.10.2224","volume":"39","author":"Monto AS","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"p_8_22","doi-asserted-by":"crossref","unstructured":"Brady MT, Sears SD, Pacini DL, etal Safety and prophylactic efAEcacy 29. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxyof low-dose rimantadine in adults during an inOuenza A epidemic. 2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of inOuenza Antimicrob Agents Chemother 1990; 34:1633 0 6. virus in ferrets. Antimicrob Agents Chemother 1995; 39:2583 0 4.","DOI":"10.1128\/AAC.39.11.2583"},{"key":"p_9_23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.241.10.1003"},{"key":"p_10_24","first-page":"86","volume":"27","author":"Nafta I","year":"1995","journal-title":"Antiviral Res"},{"key":"p_11_25","doi-asserted-by":"crossref","unstructured":"Quarles JM, Couch RB, Cate TR, Goswick CB. Comparison of amantadine possessing a novel hydrophobic interaction in the enzyme active site: and rimantadine for prevention of type A (Russian) inOuenza. Antiviral design, synthesis, and structural analysis of carbocyclic sialic acid ana-Res 1981; 1:149 0 55 logues with potent anti-inOuenza activity. J Am Chem Soc 1997; 119:","DOI":"10.1016\/0166-3542(81)90003-6"},{"key":"p_12_26","unstructured":"Pettersson RF, Hellstrom PE, Penttinen K, etal Evaluation of amantadine 681 0 90. in the prophylaxis of inOuenza A (H1N1) virus infection: a controlled 32. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. AEeld trial among young adults and high-risk patients. J Infect Dis 1980; Safety and efAEcacy of the neuraminidase inhibitor GG167 (4-guanidino-142:377 0 83. Neu5Ac2en) in experimental human inOuenza. JAMA 1996; 275:295 0"},{"key":"p_13_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/bmj.3.5724.676","volume":"3","author":"Oker-Blom N","year":"1970","journal-title":"Br Med J"},{"key":"p_14_28","unstructured":"Smorodintsev AA, Karpuhin GI, Zlydnikov DM, etal The prophylactic Hampson AW, Webster RG, eds. Options for the control of inOuenza III. effectiveness of amantadine hydrochloride in an epidemic of Hong Kong Amsterdam: Elsevier Science, 1996:718 0 25. inOuenza in Leningrad in 1969. Bull WHO 1970; 42:865 0 72. 34. Hayden FG, Osterhaus A, Treanor J, Aoki F, Keene O, GG167 Study"},{"key":"p_15_29","doi-asserted-by":"crossref","unstructured":"Hayden FG, Couch RB. Clinical and epidemiological importance of inOu- Group. Phase II studies of the therapeutic efAEcacy and safety of GG167 enza A viruses resistant to amantadine and rimantadine. Rev Med Virol [abstract H45]. In: Program and abstracts of the 36th Interscience Con-1992; 2:89 0 96. ference on Antimicrobial Agents and Chemotherapy (New Orleans).","DOI":"10.1002\/rmv.1980020205"},{"key":"p_16_30","unstructured":"Hayden FG. Amantadine and rimantadine - clinical aspects. In: Richman Washington, DC: American Society for Microbiology, 1996:171. DD, ed. Antiviral drug resistance. Chichester, UK: John Wiley & Sons, 35. Mochalova LV, Tuzikov AB, Marinina VP, et al. Synthetic polymeric 1996:59 0 77. inhibitors of inOuenza virus receptor-binding activity suppress virus"},{"key":"p_17_31","first-page":"90","volume":"23","author":"Mast EE","year":"1994","journal-title":"Antiviral Res"},{"key":"p_18_32","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.152.2.390"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/176\/Supplement_1\/S56\/2797653\/176-Supplement_1-S56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T03:40:12Z","timestamp":1557114012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/514177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":17,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["10.1086\/514177"],"URL":"https:\/\/doi.org\/10.1086\/514177","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8]]}}}